Revvity (NYSE:RVTY) Coverage Initiated at UBS Group

Investment analysts at UBS Group began coverage on shares of Revvity (NYSE:RVTY) in a research note issued on Wednesday, MarketBeat Ratings reports. The brokerage set a “neutral” rating and a $140.00 price target on the stock. UBS Group’s target price points to a potential upside of 14.85% from the company’s previous close.

RVTY has been the topic of several other research reports. Sanford C. Bernstein began coverage on shares of Revvity in a report on Friday, June 26th. They set a “market perform” rating and a $115.00 price objective on the stock. Wall Street Zen downgraded shares of Revvity from a “buy” rating to a “hold” rating in a research report on Sunday, August 16th. Royal Bank Of Canada started coverage on shares of Revvity in a research note on Tuesday, September 1st. They set a “sector perform” rating and a $135.00 price target on the stock. TD Cowen reaffirmed a “buy” rating on shares of Revvity in a report on Wednesday, July 15th. Finally, KeyCorp lifted their price objective on shares of Revvity from $125.00 to $165.00 and gave the stock an “overweight” rating in a research note on Friday. Four equities research analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $116.57.

Revvity Stock Down 4.1%

RVTY stock traded down $5.18 on Wednesday, hitting $121.90. 82,585 shares of the company’s stock were exchanged, compared to its average volume of 1,401,964. Revvity has a 12-month low of $81.22 and a 12-month high of $133.00. The firm has a 50 day moving average price of $117.12 and a two-hundred day moving average price of $102.75. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.50 and a current ratio of 1.80. The stock has a market cap of $13.60 billion, a P/E ratio of 58.37, a price-to-earnings-growth ratio of 2.37 and a beta of 1.09.

Revvity (NYSE:RVTY) last released its quarterly earnings results on Tuesday, August 4th. The company reported $1.41 EPS for the quarter, beating analysts’ consensus estimates of $1.21 by $0.20. The company had revenue of $729.69 million during the quarter, compared to analysts’ expectations of $702.96 million. Revvity had a return on equity of 8.34% and a net margin of 8.16%.The firm’s revenue was down 1.3% compared to the same quarter last year. During the same period last year, the business posted $1.18 earnings per share. Revvity has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, equities research analysts expect that Revvity will post 5.37 EPS for the current fiscal year.

Institutional Trading of Revvity

A number of hedge funds have recently modified their holdings of the stock. AQR Capital Management LLC increased its holdings in shares of Revvity by 5.2% during the 1st quarter. AQR Capital Management LLC now owns 8,449 shares of the company’s stock valued at $883,000 after purchasing an additional 420 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Revvity by 6.7% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,776 shares of the company’s stock valued at $1,246,000 after purchasing an additional 744 shares during the period. Millennium Management LLC grew its holdings in Revvity by 102.0% in the first quarter. Millennium Management LLC now owns 69,401 shares of the company’s stock valued at $7,343,000 after purchasing an additional 35,048 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Revvity by 45.5% in the first quarter. Goldman Sachs Group Inc. now owns 607,104 shares of the company’s stock valued at $64,232,000 after buying an additional 189,871 shares in the last quarter. Finally, Focus Partners Wealth increased its position in shares of Revvity by 13.0% in the first quarter. Focus Partners Wealth now owns 7,028 shares of the company’s stock valued at $744,000 after buying an additional 811 shares in the last quarter. Hedge funds and other institutional investors own 86.65% of the company’s stock.

About Revvity

Revvity, Inc is a global provider of technology-enabled solutions for the life sciences, diagnostics and applied markets. The company develops and supplies a range of products and services, including reagents and consumables, laboratory instruments, workflow automation, software analytics and technical support. Its portfolio supports applications in drug discovery, genomics, cell biology research, environmental and food safety testing, industrial quality control and clinical diagnostics.

Tracing its heritage to Perkin-Elmer, founded in 1937, Revvity began trading on the New York Stock Exchange under the ticker symbol RVTY in January 2024 following a corporate rebranding.